Mary Szela

Mary T.
Szela is President, Chief Executive Officer & Director at TriSalus Operating Life Sciences, Inc. and TriSalus Life Sciences, Inc. since 2018.
Ms. Szela is an Independent Director at Kura Oncology, Inc. since 2018.
Ms. Szela is Director at Absci Corp.
starting 2025.
Ms. Szela is Independent Director at Averin Capital Acquisition Corp.
starting 2026.
Ms. Szela is Director at Court Appointed Special Advocates of Lake County and Sail Biomedicines Inc. Former roles include Chief Executive Officer & Director at Aegerion Pharmaceuticals, Inc. in 2016; Chief Executive Officer & Director at Novelion Therapeutics, Inc. from 2016 to 2017; Co-Chief Executive Officer & Director at Melinta Subsidiary Corp.
from 2013 to 2015; Independent Director at Novo Nordisk A from 2014 to 2017; Independent Director at Receptos LLC from 2014 to 2015; Director at Zikani Therapeutics, Inc. from 2018 to 2019; Director at Suneva Medical, Inc. from 2012 to 2017; Independent Director at Coherus Oncology, Inc. from 2014 to 2021; Independent Director at Prometheus Biosciences, Inc. from 2021 to 2023; Independent Director at Alimera Sciences, Inc. from 2018 to 2021; Independent Director at Omega Therapeutics, Inc. from 2019 to 2025; SVP-Global Strategic Marketing & Services at Abbott Laboratories from 2010 to 2012; Senior Vice President at US Pharmaceuticals, Inc. from 2008 to 2009.
Education includes undergraduate and MBAistration degrees from the University of Illinois.